BioSpace News Archive

BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reports financial results for the first quarter of 2023 and filed its quarterly report on Form 10-Q for the three months ended March 31, 2023 with the Securities and Exchange Commission.

Avinger, Inc., a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, reported results for the first quarter ended March 31, 2023.

Nephros, Inc., a leading water technology company providing filtration solutions to the medical and commercial markets, announced financial results for the first quarter ended March 31, 2023.

UNION therapeutics A/S announced that Dr. Kim D. Kjøller, CEO of UNION therapeutics will present at the seminar on hidradenitis suppurativa at the 4th Annual Dermatology Drug Development Summit Europe on May 22-24, 2023, in Berlin, Germany.

Mainz Biomed N.V. announced a research collaboration with Microba Life Sciences, a precision microbiome company leveraging a world-leading technology platform for measuring the human gut microbiome to discover and develop novel therapeutics for major diseases.

Ribbon Biolabs, the DNA synthesis company, announced the appointment of Jodi Barrientos as Chief Business Officer.

Alvotech announced that it has entered into an exclusive agreement with Polifarma Ilac San. ve tic. A.S. for the commercialization in Turkey of AVT06, a proposed biosimilar to Eylea®.

MannKind Corporation announced that its Chief Executive Officer, Michael Castagna, PharmD, will participate in a Fireside Chat at the 2023 RBC Capital Markets Global Healthcare Conference on Tuesday, May 16, 2023 at 2:05 pm at the InterContinental New York Barclay.

SwanBio Therapeutics, a gene therapy company advancing AAV-based therapies for the treatment of devastating, inherited neurological conditions, has conducted a healthcare resource use study confirming the substantial burden and economic impact of AMN on both men and women.

Reata Pharmaceuticals, Inc. announced financial results for the first quarter of 2023 and provided an update on the Company’s business operations and clinical development programs.